{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bangaru S"],"funding":["NCRR NIH HHS","National Institute of Allergy and Infectious Diseases Division of Intramural Research","NIAID NIH HHS","Gates Foundation","NIGMS NIH HHS"],"pagination":["115986"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12486969"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["44(7)"],"pubmed_abstract":["Design and development of improved COVID-19 vaccines that can induce broad, durable immunity against emerging variants require an in-depth understanding of the antigenic and immunogenic properties of vaccines utilizing existing platforms. Here, we examine the antigenicity of two original COVID-19 vaccines by performing secondary analyses of the clinical trials for mRNA-1273 (this study was registered at ClinicalTrials.gov NCT04283461) and NVX-CoV2373 (this study was registered at ClinicalTrials.gov NCT04368988) using electron microscopy-based polyclonal epitope mapping (EMPEM). Both vaccines induce diverse polyclonal antibody (pAb) responses to the N-terminal domain (NTD) in addition to the receptor-binding domain of the Spike protein, with the NTD supersite being an immunodominant epitope"],"journal":["Cell reports"],"pubmed_title":["Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines."],"pmcid":["PMC12486969"],"funding_grant_id":["R01 AI127521","UM1 AI144462","INV-004923","P41 RR001081","R24 GM154185"],"pubmed_authors":["Fernandez-Quintero ML","Guebre-Xabier M","Edwards DK","Das R","Smith G","Bangaru S","Torrents de la Pena A","Graham BS","Seder RA","Torres JL","Sewall LM","Patel N","Girard B","Jackson AM","Nogal B","Copps J","Rehman A","Corbett-Helaire KS","Ward AB","Richey ST"],"additional_accession":[]},"is_claimable":false,"name":"Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.","description":"Design and development of improved COVID-19 vaccines that can induce broad, durable immunity against emerging variants require an in-depth understanding of the antigenic and immunogenic properties of vaccines utilizing existing platforms. Here, we examine the antigenicity of two original COVID-19 vaccines by performing secondary analyses of the clinical trials for mRNA-1273 (this study was registered at ClinicalTrials.gov NCT04283461) and NVX-CoV2373 (this study was registered at ClinicalTrials.gov NCT04368988) using electron microscopy-based polyclonal epitope mapping (EMPEM). Both vaccines induce diverse polyclonal antibody (pAb) responses to the N-terminal domain (NTD) in addition to the receptor-binding domain of the Spike protein, with the NTD supersite being an immunodominant epitope","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-06-04T01:47:34.584Z","creation":"2026-05-04T03:13:54.364Z"},"accession":"S-EPMC12486969","cross_references":{"pubmed":["40632654"],"doi":["10.1016/j.celrep.2025.115986"]}}